Sunset in Puerta del Sol, Madrid
Not in Madrido – In our latest ESMO20 Preview, we take a look at five emerging areas of cancer drug development involving early stage pipelines and highlight some important features and benefits to watch out for.
These topics won’t be on everyone’s radar, especially if the focus is on the big phase 3 trial readouts, yet they can teach us much about new combinations and future pipeline evolution.
Who’s actively moving novel approaches along and who’s sitting on their laurels?
After covering biomarkers to watch out for yesterday, we now take a dive into what’s looking interesting in terms of novel targets and the fresh new opportunities for the not faint of heart…
To learn more from our oncology analysis and get a heads up on insights and commentary pertaining to ESMO 2020, subscribers can log-in or you can click to gain access to BSB Premium Content.
Embedded deep in any conference database of abstracts are often important findings, which tend to be overlooked by many observers in the rush to focus on the more obvious candidates.
Time to scale the cliff on a previously little known and undruggable target!
This preview and accompanying thought leader interview explores one such underrated avenue of research.
There is a lot to be said when we have clear signals from our knowledge of the underlying biology in front of us because they inform where therapeutic intervention should be both rational and fruitful.
Is this actually the case in practice?
We dug deeper to find out what’s really happening…
To learn more from our oncology analysis and get a heads up on insights and commentary emerging from the ASCO meeting together with our latest KOL interview, subscribers can log-in or you can click to gain access to BSB Premium Content.